Interim Report 1 January – 30 June 2022

• 72% growth in the number of active customers during the quarter – Episurf is experiencing a faster adoption and increased acceptance for the Episealer® technology
• In six months 2022, Episurf has already exceeded the full year 2021 figure for the number of active customers
• 42% growth in gross order intake and a strong cash position

”The main priority in our commercial efforts right now is to grow the user base, and we are clearly seeing that our ability to generate new customers is better than ever. In fact, during the first two quarters of 2022, we have already had as many customers (66) as we had for the full year 2021. Volumes will increase with each customer as pandemic-related backlogs are worked through and when user experience from the Episealer® increases”, says Pål Ryfors, CEO Episurf Medical.

Second quarter 2022 compared to 2021, Group

• Gross order intake amounted to SEK 2.0m (1.4)
• Order book amounted to SEK 1.5m (1.3)
• Group net sales amounted to SEK 1.9m (2.0)
• Loss for the period amounted to SEK -19.4m (-17.7)
• Earnings per share amounted to SEK -0.07(-0.08)

First six months 2022 compared to 2021, Group

• Gross order intake amounted to SEK 3.6m (3.6)
• Group net sales amounted to SEK 3.4m (3.6)
• Loss for the period amounted to SEK -35.8m (-34.4)
• Earnings per share amounted to SEK -0.13(-0.16)

Significant events during the second quarter

• Promising results from comparative study with Episealer® were accepted for presentation at German orthopaedic congress
• Episurf Medical submitted follow-up 510(k) application for Episealer® Patellofemoral System that is now under substantive review at the US FDA
• Prospective investigator-initiated study for 2 years’ follow-up of Episealer® Talus patient initiated
• First knee implant Episealer® surgery was planned in Saudi Arabia, and India were planned
• First Episealer® Talus surgery performed in Portugal and Belgium
• 5-year follow-up data presented at several clinical congresses

Significant events after the second quarter

• Presentation by Prof Karl Eriksson about the Episealer® Knee technology and clinical results at the 5^th International Conference on Meniscus Science and Surgery in Luxembourg

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on July 15, 2022.

Tags: